1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England). 2015 Jan;385(9963):117–71.
2. Ávila-Burgos L, Cahuana-Hurtado L, González-Domínguez D, Aracena-Genao B, Montañez-Hernández JC, Serván-Mori EE, RiveraPeña G. Cuentas en diabetes mellitus, enfermedades cardiovasculares y obesidad, México 2006. Ciudad de México Cuernavaca, México: Instituto Nacional de Salud Publica.
3. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal Organ [Internet]. 2013;102. Available from: http://apps.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf
4. Bloom DE, Cafiero E, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S, et al. The global economic burden of noncommunicable diseases. Program on the Global Demography of Aging; 2012.
5. Laslett LJ, Alagona P, Clark BA, Drozda JP, Saldivar F, Wilson SR, et al. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues: A report from the american college of cardiology. J Am Coll Cardiol [Internet]. 2012;60(25 SUPPL.):S1–49. Available from: http://dx.doi.org/10.1016/j.jacc.2012.11.002
6. Barquera S, Tovar-Guzmán V, Campos-Nonato I, González-Villalpando C, Rivera-Dommarco J. Geography of diabetes mellitus mortality in Mexico: An epidemiologic transition analysis. Arch Med Res. 2003;34(5):407–14.
7. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Publica Mex [Internet]. 2010;52(2). Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-36342010000700011&lng=en&nrm=iso&tlng=en
8. Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza A, Rivera-Dommarco J a. Prevalencia de obesidad en adultos mexicanos 2000-2012. Salud Publica Mex [Internet]. 2013;55(.2):151–60. Available from: http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0036-36342013000800012&lng=en&nrm=iso&tlng=es
9. Aguilar-Salinas CA, Gomez-Perez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52 Suppl 1:S44-53.
10. Barquera S, Pedroza-Tobias A, Medina C. Cardiovascular diseases in mega-countries. Curr Opin Lipidol. 2016;27(4):329–44.
11. Barquera S, Pedroza-Tobías A, Medina C, Hernández-Barrera L, Bibbins-Domingo K, Lozano R, et al. Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease. Arch Med Res. 2015;46(5):328–38.
12. Rivera JA, Barquera S, Campirano F, Campos I, Safdie M, Tovar V. Epidemiological and nutritional transition in Mexico: rapid increase of non-communicable chronic diseases and obesity. Public Health Nutr. 2002 Feb;5(1A):113–22.
13. Stevens G, Dias RH, Thomas KJA, Rivera JA, Carvalho N, Barquera S, et al. Characterizing the epidemiological transition in Mexico: National and subnational burden of diseases, injuries, and risk factors. PLoS Med. 2008;5(6):0900–10.
14. Stern D, Piernas C, Barquera S, Rivera JA, Popkin BM. Caloric beverages were major sources of energy among children and adults in Mexico, 1999-2012. J Nutr. 2014 Jun;144(6):949–56.
15. Barquera S, Campirano F, Bonvecchio A, Hernandez-Barrera L, Rivera JA, Popkin BM. Caloric beverage consumption patterns in Mexican children. Nutr J. 2010 Oct;9:47.
16. Barquera S, Hernandez-Barrera L, Tolentino ML, Espinosa J, Ng SW, Rivera JA, et al. Energy intake from beverages is increasing among Mexican adolescents and adults. J Nutr. 2008 Dec;138(12):2454–61.
17. Flores M, Macias N, Rivera M, Lozada A, Barquera S, Rivera-Dommarco J, et al. Dietary patterns in Mexican adults are associated with risk of being overweight or obese. J Nutr. 2010 Oct;140(10):1869–73.
18. Barquera S, Campos-Nonato I, Hernandez-Barrera L, Villalpando S, Rodriguez-Gilabert C, Durazo-Arvizu R, et al. Hypertension in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex. 2010;52 Suppl 1:S63-71.
19. Popkin BM. Nutrition Transition and the Global Diabetes Epidemic. Curr Diab Rep. 2015;15(9).
20. Douglas KA, Yang G, McQueen D V., Puska P. Mega Country Health Promotion Network Surveillance Initiative. In: Douglas KA, Yang G, McQueen D V., Puska P, editors. Global Behavioral Risk Factor Surveillance. Boston, MA: Springer; 2003. p. 179–96.
21. Kennedy E. Healthy lifestyles. healthy people - The Mega Country Health Promotion Network. Asia Pac J Clin Nutr. 2002;11 Suppl 8:S738--S739.
22. Stewart F. Capabilities and Human Development: Beyond the individual - the critical role of social institutions and social competencies. Hum Dev Reports - UNDP. 2013;03:1–20.
23. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement (Chinese edition). J Chinese Integr Med. 2009;7(9):889–96.
24. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol [Internet]. 2009;62(10):e1-34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19631507
25. Olaiz-Fernández G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando Hernández S, Hernández-Avila M, Sepúlveda-Amor J. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública, 2006.
26. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, Romero-Martínez M, Hernández-Ávila M. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Púb.
27. Instituo Mexicano del Seguro Social (IMSS). Portal de compras del IMSS [Internet]. [cited 2018 Jul 9]. Available from: http://compras.imss.gob.mx/
28. Institute for Health Metrics and Evaluation (IHME). GBDCompareDataVisualization. Seattle, WA: IHME, University of Washington, 2016. Available from http:// vizhub.healthdata.org/gbd-compare. (Accessed [January 20, 2018]).
29. Organization WH. Global health observatory data repository. 2013.
30. Gomez-Perez FJ, Rojas R, Villalpando S, Barquera S, Rull J, Aguilar-Salinas CA. Prevention of cardiovascular disease based on lipid lowering treatment: a challenge for the Mexican health system. Salud Publica Mex. 2010;52 Suppl 1:S54-62.
31. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May;285(19):2486–97.
32. Carroll MD, Fryar CD, Nguyen DT. Total and High-density Lipoprotein Cholesterol in Adults: United States, 2015-2016 Key findings Data from the National Health and Nutrition Examination Survey. 2015;(290):2015–6. Available from: https://www.cdc.gov/nchs/data/databriefs/db290_table.pdf#2.
33. Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2012;6(4):325–30.
34. Kuklina E V, Carroll MD, Shaw KM, Hirsch R. Trends in high LDL cholesterol, cholesterol-lowering medication use, and dietary saturated-fat intake: United States, 1976-2010. NCHS Data Brief [Internet]. 2013;(117):1–8. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4401469&tool=pmcentrez&rendertype=abstract
35. National Health and Nutrition Survey in Japan. Ministry of Health, Labour, and Welfare; 2015. Available at: http://www.mhlw.go.jp/toukei itiran/gaiyo/k-eisei.html.
36. Lin CF, Chang YH, Chien SC, Lin YH, Yeh HY. Epidemiology of Dyslipidemia in the Asia Pacific Region. Int J Gerontol. 2018;12(1):2–6.
37. Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, et al. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014;9(5):e96808.
38. Oguoma VM, Nwose EU, Ulasi II, Akintunde AA, Chukwukelu EE, Bwititi PT, et al. Cardiovascular disease risk factors in a Nigerian population with impaired fasting blood glucose level and diabetes mellitus. BMC Public Health [Internet]. 2017;17(1):1–9. Available from: http://dx.doi.org/10.1186/s12889-016-3910-3
39. Huang Y, Gao L, Xie X, Tan SC. Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control. Popul Health Metr. 2014;12(1):28.
40. Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults. Int J Cardiol [Internet]. 2018;260:196–203. Available from: https://doi.org/10.1016/j.ijcard.2017.12.069
41. Santos RD, Bensenor IM, Pereira AC, Lotufo PA. Dyslipidemia according to gender and race: The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Clin Lipidol. 2016;10(6):1362–8.
42. Lotufo PA, Santos RD, Sposito AC, Bertolami M, Rocha-Faria Neto J, Izar MC, et al. Self-Reported High-Cholesterol Prevalence in the Brazilian Population: Analysis of the 2013 National Health Survey. Arq Bras Cardiol. 2017;411–6.
43. Figueroa-Lara A, Gonzalez-Block MA, Alarcon-Irigoyen J. Medical Expenditure for Chronic Diseases in Mexico: The Case of Selected Diagnoses Treated by the Largest Care Providers. PLoS One. 2016;11(1):e0145177.
44. Stevens B, Pezzullo L, Verdian L, Tomlinson J, Estrada-Aguilar C, George A, et al. The economic burden of hypertension, heart failure, myocardial infarction, and atrial fibrillation in Mexico. Arch Cardiol Mex. 2018 Apr;
45. Arredondo A, Cuadra SM, Duarte MB. Challenges of the epidemiological and economic burdens associated with hypertension in middle income countries: Evidence from Mexico Chronic Disease epidemiology. BMC Public Health [Internet]. 2015;15(1):1–7. Available from: http://dx.doi.org/10.1186/s12889-015-2430-x
46. Arredondo A, Duarte MB, Cuadra SM. Epidemiological and financial indicators of hypertension in older adults in Mexico: challenges for health planning and management in Latin America. Int J Health Plann Manage. 2017;32(2):e121–36.
47. Butland B, Jebb S, Kopelman P et al. Foresight Tackling Obesities: Future Choices - Project Report. 2007. London: Government Office for Science.
48. Kopelman P, Jebb SA & Butland B. Executive summary: Foresight: “Tackling Obesities: Future Choices” project. Obes Rev. 2007;8:Suppl1:vi-ix.
49. McPherson K, Marsh T & Brown M Foresight. Tackling Obesities: Future Choices - Modelling Future Trends in Obesity & Their Impact on Health. 2007. London: Government Office for Science.
50. Rtveladze K, Marsh T, Barquera S, Sanchez Romero LM, Levy D, Melendez G, et al. Obesity prevalence in Mexico: impact on health and economic burden. Public Health Nutr. 2014 Jan;17(1):233–9.
51. Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JAN, Visseren FLJ. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb;6(2).
52. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, et al. US Spending on Personal Health Care and Public Health, 1996-2013. JAMA. 2016 Dec;316(24):2627–46.
53. Birabi BN, Oke KI, Dienye PO, Okafor UC. Cost burden of post stroke condition in Nigeria: a pilot study. Glob J Health Sci. 2012;4(6):17.
54. Basu S, Stuckler D, Vellakkal S, Ebrahim S. Dietary salt reduction and cardiovascular disease rates in India: a mathematical model. PLoS One. 2012;7(9):e44037.
55. Basu S, Babiarz KS, Ebrahim S, Vellakkal S, Stuckler D, Goldhaber-Fiebert JD. Palm oil taxes and cardiovascular disease mortality in India: economic-epidemiologic model. BMJ. 2013;347:f6048.
56. Bertram MY, Sweeny K, Lauer JA, Chisholm D, Sheehan P, Rasmussen B, et al. Investing in non-communicable diseases: an estimation of the return on investment for prevention and treatment services. Lancet. 2018;
57. Bloom DE, Cafiero-Fonseca ET, McGovern ME, Prettner K, Stanciole A, Weiss J, et al. The macroeconomic impact of non-communicable diseases in China and India: Estimates, projections, and comparisons. J Econ Ageing [Internet]. 2014;4:100–11. Available from: http://dx.doi.org/10.1016/j.jeoa.2014.08.003
58. Bloom DE, Chen S, Kuhn M, McGovern ME, Oxley L, Prettner K. The economic burden of chronic diseases: Estimates and projections for China, Japan, and South Korea. J Econ Ageing [Internet]. 2018 Sep 26 [cited 2019 Jun 19];100163. Available from: https://www.sciencedirect.com/science/article/pii/S2212828X18300744
59. Stevens B, Pezzullo L, Verdian L, Tomlinson J, George A, Bacal F. The Economic Burden of Heart Conditions in Brazil. Arq Bras Cardiol. 2018;(November 2016):29–36.
60. Association AH. Cardiovascular disease: A costly burden for America projections through 2035. 2017.
61. Dunbar SB, Khavjou OA, Bakas T, Hunt G, Kirch RA, Leib AR, et al. Projected Costs of Informal Caregiving for Cardiovascular Disease: 2015 to 2035: A Policy Statement From the American Heart Association. Circulation. 2018 May;137(19):e558–77.
62. Gochi T, Matsumoto K, Amin R, Kitazawa T, Seto K, Hasegawa T. Cost of illness of ischemic heart disease in Japan: A time trend and future projections. Environ Health Prev Med. 2018;23(1):1–7.
63. Stevens W, Peneva D, Li JZ, Liu LZ, Liu G, Gao R, et al. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China. BMC Health Serv Res. 2016 May;16:175.
64. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M. Heart Disease and Stroke Statistics—2017 Update. Vol. 135, Circulation. 2017. 146–603 p.
65. Levi J, Segal LM, Juliano C. Prevention for a healthier America: investments in disease prevention yield significant savings, stronger communities. Trust for America’s Health; 2008.
66. Chen W-W, Gao R-L, Liu L-S, Zhu M-L, Wang W, Wang Y-J, et al. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol [Internet]. 2017;14(1):1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28270835%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5329726
67. Wang S, Marquez P, Langenbrunner J, Niessen L, Suhrcke M, Song F. Toward a healthy and harmonious life in China: stemming the rising tide of non-communicable diseases. Washingt World Bank. 2011;
68. Matsumoto K, Hanaoka S, Wu Y, Hasegawa T. Comprehensive Cost of Illness of Three Major Diseases in Japan. J Stroke Cerebrovasc Dis. 2017;26(9):1934–40.
69. Siqueira A de SE, Siqueira-Filho AG de, Land MGP. Analysis of the Economic Impact of Cardiovascular Diseases in the Last Five Years in Brazil. Arq Bras Cardiol. 2017;109(1):39–46.
70. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370(9603):1929–38.
71. Campos-Nonato I, Hernández-Barrera L, Pedroza-Tobías A, Medina C, Barquera S. Hipertensión arterial en adultos mexicanos: prevalencia, diagnóstico y tipo de tratamiento. Ensanut MC 2016. Salud Publica Mex [Internet]. 2018;60(3, may-jun):233. Available from: http://www.saludpublica.mx/index.php/spm/article/view/8813
72. Chomistek AK, Chiuve SE, Eliassen AH, Mukamal KJ, Willett WC, Rimm EB. Healthy lifestyle in the primordial prevention of cardiovascular disease among young women. J Am Coll Cardiol. 2015 Jan;65(1):43–51.
73. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000 Jul;343(1):16–22.
74. Chiuve SE, Rexrode KM, Spiegelman D, Logroscino G, Manson JE, Rimm EB. Primary prevention of stroke by healthy lifestyle. Circulation. 2008 Aug;118(9):947–54.
75. Sánchez-Romero LM, Penko J, Coxson PG, Fernández A, Mason A, Moran AE, et al. Projected Impact of Mexico’s Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study. PLoS Med. 2016;13(11):1–17.
76. Peñalvo JL, Cudhea F, Micha R, Rehm CD, Afshin A, Whitsel L, et al. The potential impact of food taxes and subsidies on cardiovascular disease and diabetes burden and disparities in the United States. BMC Med. 2017;15(1):1–13.
77. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul;63(25 Pt B):2889–934.
78. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb;311(5):507–20.
79. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation. 1997 Nov;96(9):3243–7.
80. The CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes. Jama [Internet]. 2002;287(19):2542. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.287.19.2542
81. Córdova-Villalobos JA, Barriguete-Meléndez JA, Lara-Esqueda A, Barquera S, Rosas-Peralta M, Hernández-Avila M, et al. Chronic non-communicable diseases in Mexico: Epidemiologic synopsis and integral prevention. Salud Publica Mex [Internet]. 2008;50(5):419–27. Available from: http://bvs.insp.mx/rsp/_files/File/2008/Septiembre Octubre/9-panorama.pdf%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=18852939%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/18852939
82. Moran AE, Odden MC, Thanataveerat A, Tzong KY, Rasmussen PW, Guzman D, et al. Cost-Effectiveness of Hypertension Therapy According to 2014 Guidelines. N Engl J Med [Internet]. 2015 Jan 28;372(5):447–55. Available from: http://dx.doi.org/10.1056/NEJMsa1406751
83. Kondo T, Osugi S, Shimokata K, Honjo H, Morita Y, Maeda K, et al. Smoking and Smoking Cessation in Relation to All-Cause Mortality and Cardiovascular Events in 25,464 Healthy Male Japanese Workers. Circ J [Internet]. 2011;75(12):2885–92. Available from: http://joi.jlc.jst.go.jp/JST.JSTAGE/circj/CJ-11-0416?from=CrossRef
84. Rivera J, Barquera S, González-Cossío T, Olaiz G, Sepúlveda J. Nutrition transition in Mexico and in other Latin American countries. Nutr Rev. 2004;62(7 Pt 2):S149–57.
85. Marron-Ponce JA, Sanchez-Pimienta TG, Louzada ML da C, Batis C. Energy contribution of NOVA food groups and sociodemographic determinants of ultra-processed food consumption in the Mexican population. Public Health Nutr. 2018 Jan;21(1):87–93.
86. Ponce X, Rodriguez-Ramirez S, Mundo-Rosas V, Shamah T, Barquera S, Gonzalez de Cossio T. Dietary quality indices vary with sociodemographic variables and anthropometric status among Mexican adults: a cross-sectional study. Results from the 2006 National Health and Nutrition Survey. Public Health Nutr. 2014 Aug;17(8):1717–28.
87. National Population Commission - NPC/Nigeria and ICF International. Demographic and Health Survey 2013. N. Abuja, Nigeria; 2014.
88. Dandona R, Pandey A, Dandona L. A review of national health surveys in India. World Heal Organ Bull. 2016;94(4):286–96.
89. Garcez MR, Pereira JL, Fontanelli M de M, Marchioni DML, Fisberg RM. Prevalence of Dyslipidemia According to the Nutritional Status in a Representative Sample of São Paulo. Arq Bras Cardiol. 2014;476–84.
90. Franssen R, Monajemi H, Stroes ESG, Kastelein JJP. Obesity and dyslipidemia. Med Clin North Am. 2011 Sep;95(5):893–902.
91. Klop B, Elte JWF, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013 Apr;5(4):1218–40.
92. Castelli W. Lipoproteins and cardiovascular disease: biological basis and epidemiological studies. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 1998;1(2):105–9.
93. Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics. 2015 Jul;33(7):673–89.
94. Barquera S, Flores M, Olaiz-Fernández G, Monterrubio E, Villalpando S, González C, et al. Dyslipidemias and obesity in Mexico. Salud Publica Mex. 2007;49:s338–47.
95. Guo F, Garvey WT. Trends in Cardiovascular Health Metrics in Obese Adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014. J Am Heart Assoc. 2016 Jul;5(7).
96. Mitchell AP, Simpson RJ. Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States. BMC Res Notes. 2012 Jul;5:373.
97. Berra K. Lipid-lowering therapy today: Treating the high-risk cardiovascular patient. J Cardiovasc Nurs. 2008;23(5):414–21.
98. Schwiesow SJ, Nappi JM, Ragucci KR. Assessment of compliance with lipid guidelines in an academic medical center. Ann Pharmacother. 2006 Jan;40(1):27–31.
99. Zafrir B, Cohen S. Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Eur J Intern Med. 2006 Nov;17(7):495–9.
100. Rivera JA, Pedraza LS, Aburto TC, Batis C, Sanchez-Pimienta TG, Gonzalez de Cosio T, et al. Overview of the Dietary Intakes of the Mexican Population: Results from the National Health and Nutrition Survey 2012. J Nutr. 2016 Sep;146(9):1851S-5S.
101. Medina C, Janssen I, Campos I, Barquera S. Physical inactivity prevalence and trends among Mexican adults: Results from the National Health and Nutrition Survey (ENSANUT) 2006 and 2012. BMC Public Health. 2013;13(1).
102. Medina C, Tolentino-Mayo L, Lopez-Ridaura R, Barquera S. Evidence of increasing sedentarism in Mexico City during the last decade: Sitting time prevalence, trends, and associations with obesity and diabetes. PLoS One. 2017;12(12):e0188518.
103. Danchin N, Almahmeed W, Al-Rasadi K, Azuri J, Berrah A, Cuneo CA, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018;
104. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May;376(18):1713–22.
105. Schwartz GG, Szarek M, Bhatt DL, et al. Alirocumab in patients after acute coronary syndrome. Orlando, FL: American College of Cardiology, 2018.
106. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 2016 Aug;316(7):743–53.
107. Svatikova A, Kopecky SL. Cholesterol Management in the Era of PCSK9 Inhibitors. Curr Cardiol Rep. 2017 Sep;19(9):83.
108. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data. Lancet [Internet]. 2016;387(10013):61–9. Available from: http://dx.doi.org/10.1016/S0140-6736(15)00469-9
109. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet (London, England). 2011 Oct;378(9798):1231–43.
110. Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. Circulation. 2016 May;133(21):2076–85.
111. Beall RF, Schwalm J-DR, Huffman MD, McCready T, Yusuf S, Attaran A. Could patents interfere with the development of a cardiovascular polypill? J Transl Med. 2016 Aug;14(1):242.
112. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007 Aug;120(8):713–9.
113. Huffman MD. The Polypill: From Promise to Pragmatism. PLoS Med. 2015 Aug;12(8):e1001862.
114. Elley CR, Gupta AK, Webster R, Selak V, Jun M, Patel A, et al. The efficacy and tolerability of “polypills”: meta-analysis of randomised controlled trials. PLoS One. 2012;7(12):e52145.
115. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertens (Dallas, Tex 1979). 2010 Feb;55(2):399–407.
116. Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet (London, England). 2009 Apr;373(9672):1341–51.
117. Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, et al. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One. 2011;6(5):e19857.
118. Huffman MD, Rao KD, Pichon-Riviere A, Zhao D, Harikrishnan S, Ramaiya K, et al. A cross-sectional study of the microeconomic impact of cardiovascular disease hospitalization in four low- and middle-income countries. PLoS One. 2011;6(6):e20821.
119. Si Y, Zhou Z, Su M, Ma M, Xu Y, Heitner J. Catastrophic healthcare expenditure and its inequality for households with hypertension: Evidence from the rural areas of Shaanxi Province in China. Int J Equity Health. 2017;16(1):1–12.
120. Sun J, Liabsuetrakul T, Fan Y, Mcneil E. Protecting patients with cardiovascular diseases from catastrophic health expenditure and impoverishment by health finance reform. Trop Med Int Heal. 2015;20(12):1846–54.
121. Baeza-Cruz G, Peniche-Otero G, Alva-Esqueda ME, Naranjo-Muedano M, Soria-Suárez N, Morales-Flores HJ. Análisis de costo de la enfermedad, del tratamiento, las complicaciones e intervenciones de la hipercolesterolemia en México en 2016. Value Heal Reg Issues [Internet]. 2018;17:56–63. Available from: http://dx.doi.org/10.1016/j.vhri.2017.12.003
122. Thow AM, Downs S, Jan S. A systematic review of the effectiveness of food taxes and subsidies to improve diets: understanding the recent evidence. Nutr Rev. 2014 Sep;72(9):551–65.
123. Hawkes C, Organization WH. Nutrition labels and health claims: the global regulatory environment. 2004;
124. Colchero MA, Popkin BM, Rivera JA, Ng SW. Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: observational study. BMJ. 2016 Jan;352:h6704.
125. Colchero MA, Rivera-Dommarco J, Popkin BM, Ng SW. In Mexico, Evidence Of Sustained Consumer Response Two Years After Implementing A Sugar-Sweetened Beverage Tax. Health Aff (Millwood). 2017 Mar;36(3):564–71.
126. Batis C, Rivera JA, Popkin BM, Taillie LS. First-Year Evaluation of Mexico’s Tax on Nonessential Energy-Dense Foods: An Observational Study. PLoS Med. 2016 Jul;13(7):e1002057.
127. Silver LD, Ng SW, Ryan-Ibarra S, Taillie LS, Induni M, Miles DR, et al. Changes in prices, sales, consumer spending, and beverage consumption one year after a tax on sugar-sweetened beverages in Berkeley, California, US: A before-and-after study. PLoS Med. 2017 Apr;14(4):e1002283.
128. Falbe J, Thompson HR, Becker CM, Rojas N, McCulloch CE, Madsen KA. Impact of the Berkeley Excise Tax on Sugar-Sweetened Beverage Consumption. Am J Public Health. 2016 Oct;106(10):1865–71.
129. Bascunan J, Cuadrado C. Effectiveness of sugar-sweetened beverages taxes to reduce obesity: evidence brief for policy. Medwave. 2017 Oct;17(8):e7054.